News | June 24, 2024
MediPharm Labs acquires advanced medical cannabis delivery method technology from Remidose Aerosols
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
The company will now explore a buyer for its manufacturing site and exit in due course
The Issue opened on June 18, 2024 and closed on June 21, 2024
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
